|
1
|
Seeman P: All roads to schizophrenia lead
to dopamine supersensitivity and elevated dopamine D2(high)
receptors. CNS Neurosci Ther. 17:118–132. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Trifu S, Vladuti A and Popescu A:
Neuroendocrine aspects of pregnancy and postpartum depression. Acta
Endocrinol (Bucur). 15:410–415. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Di Paolo T: Modulation of brain dopamine
transmission by sex steroids. Rev Neurosci. 5:27–41.
1994.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Trifu S and Gutt A: Interpretative process
- from utilization of predominant to psychotic decompensation.
Procedia Soc Behav Sci. 187:429–433. 2014.
|
|
5
|
Picchioni MM and Murray RM: Schizophrenia.
BMJ. 335:91–95. 2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kiliçaslan EE, Erol A, Zengin B, Çetinay
Aydin P and Mete L: Association between age at onset of
schizophrenia and age at menarche. Noro Psikiyatr Ars. 51:211–215.
2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lindamer LA, Lohr JB, Harris MJ and Jeste
DV: Sex, estrogen, and schizophrenia. Psychopharmacol Bull.
33:221–228. 1997.PubMed/NCBI
|
|
8
|
Castle DJ, Abel K, Takei N and Murray RM:
Sex differences in schizophrenia: Hormonal effect or subtypes?
Schizophr Bull. 21:1–12. 1995.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Riecher-Rössler A and Häfner H:
Schizophrenia and oestrogens - is there an association? Eur Arch
Psychiatry Clin Neurosci. 242:323–328. 1993.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Trifu S, Mihailescu R, Stegarescu S and
Ion I: Evolutional perspective over some key-aspects in psychiatry
In: Theoretical and Applied in Psychology (SICAP23): Psychology and
ongoing development. Editografica, Bologna, p179, 2016.
|
|
11
|
Guz H: Schizophrenia and sex. Anatol J
Psychiatry. 3:180–185. 2000.
|
|
12
|
Trifu S: Dissociative identity disorder
Psychotic functioning and impairment of growing-up processes. J
Educ Sci Psychol. 9:102–108. 2019.
|
|
13
|
McEwen BS and Alves SE: Estrogen actions
in the central nervous system. Endocr Rev. 20:279–307.
1999.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Huber TJ, Borsutzky M, Schneider U and
Emrich HM: Psychotic disorders and gonadal function: Evidence
supporting the oestrogen hypothesis. Acta Psychiatr Scand.
109:269–274. 2004.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bergemann N, Mundt C, Parzer P, Pakrasi M,
Eckstein-Mannsperger U, Haisch S, Salbach B, Klinga K, Runnebaum B
and Resch F: Estrogen as an adjuvant therapy to antipsychotics does
not prevent relapse in women suffering from schizophrenia: Results
of a placebo-controlled double-blind study. Schizophr Res.
74:125–134. 2005.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Nopoulos P, Flaum M and Andreasen NC: Sex
differences in brain morphology in schizophrenia. Am J Psychiatry.
154:1648–1654. 1997.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bryant NL, Buchanan RW, Vladar K, Breier A
and Rothman M: Sex differences in temporal lobe structures of
patients with schizophrenia: A volumetric MRI study. Am J
Psychiatry. 156:603–609. 1999.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rao ML and Kölsch H: Effects of estrogen
on brain development and neuroprotection - implications for
negative symptoms in schizophrenia. Psychoneuroendocrinology. 28
(Suppl 2):83–96. 2003.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Reilly TJ, Sagnay de la Bastida VC, Joyce
DW, Cullen AE and McGuire P: Exacerbation of psychosis during the
perimenstrual phase of the menstrual cycle: Systematic review and
meta-analysis. Schizophr Bull. 46:78–90. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Michael Deans PJ, Shum C, Perfect L,
Conforti M, Duarte R, Bhattacharyya S, Brandon N, Price J and
Srivastava D: Investigating the mechanisms underlying the
beneficial effects of estrogens in schizophrenia. Schizophr Bull.
44 (Suppl 1)(S105)2018.
|
|
21
|
Bergemann N, Parzer P, Runnebaum B, Resch
F and Mundt C: Estrogen, menstrual cycle phases, and
psychopathology in women suffering from schizophrenia. Psychol Med.
37:1427–1436. 2007.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ray P, Mandal N and Sinha VK: Change of
symptoms of schizophrenia across phases of menstrual cycle. Arch
Women Ment Health. 23:113–122. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Choi SH, Kang SB and Joe SH: Changes in
premenstrual symptoms in women with schizophrenia: A prospective
study. Psychosom Med. 63:822–829. 2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hodgetts S and Hausmann M: Antipsychotic
effects of sex hormones and atypical hemispheric asymmetries.
Cortex. 127:313–332. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lascurain MB, Camuñas-Palacín A, Thomas N,
Breadon C, Gavrilidis E, Hudaib AR, Gurvich C and Kulkarni J:
Improvement in depression with oestrogen treatment in women with
schizophrenia. Arch Womens Ment Health. 23:149–154. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bergemann N, Parzer P, Nagl I, Salbach B,
Runnebaum B, Mundt CH and Resch F: Acute psychiatric admission and
menstrual cycle phase in women with schizophrenia. Arch Women Ment
Health. 5:119–126. 2002.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Montgomery J, Winterbottom E, Jessani M,
Kohegyi E, Fulmer J, Seamonds B and Josiassen RC: Prevalence of
hyperprolactinemia in schizophrenia: Association with typical and
atypical antipsychotic treatment. J Clin Psychiatry. 65:1491–1498.
2004.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ishioka M, Yasui-Furukori N, Sugawara N,
Furukori H, Kudo S and Nakamura K: Hyperprolactinemia during
antipsychotics treatment increases the level of coagulation
markers. Neuropsychiatr Dis Treat. 11:477–484. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gogos A, Sbisa AM, Sun J, Gibbons A,
Udawela M and Dean B: A role for estrogen in schizophrenia:
Clinical and preclinical findings. Int J Endocrinol.
2015(615356)2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Begemann MJ, Dekker CF, van Lunenburg M
and Sommer IE: Estrogen augmentation in schizophrenia: A
quantitative review of current evidence. Schizophr Res.
141:179–184. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Heringa SM, Begemann MJ, Goverde AJ and
Sommer IE: Sex hormones and oxytocin augmentation strategies in
schizophrenia: A quantitative review. Schizophr Res. 168:603–613.
2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang Q, Dong X, Wang Y and Li X:
Raloxifene as an adjunctive treatment for postmenopausal women with
schizophrenia: A meta-analysis of randomized controlled trials.
Arch Women Ment Health. 21:31–41. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kianimehr G, Fatehi F, Hashempoor S,
Khodaei-Ardakani MR, Rezaei F, Nazari A, Kashani L and Akhondzadeh
S: Raloxifene adjunctive therapy for postmenopausal women suffering
from chronic schizophrenia: A randomized double-blind and placebo
controlled trial. Daru. 22(55)2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Usall J, Huerta-Ramos E, Labad J, Cobo J,
Núñez C, Creus M, Parés GG, Cuadras D, Franco J, Miquel E, et al:
RALOPSYCAT Group: Raloxifene as an adjunctive treatment for
postmenopausal women with schizophrenia: A 24-week double-blind,
randomized, parallel, placebo-controlled trial. Schizophr Bull.
42:309–317. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Khodaie-Ardakani MR, Khosravi M, Zarinfard
R, Nejati S, Mohsenian A, Tabrizi M and Akhondzadeh S: A
placebo-controlled study of raloxifene added to risperidone in men
with chronic schizophrenia. Acta Med Iran. 53:337–345.
2015.PubMed/NCBI
|
|
36
|
Cummings SR, Eckert S, Krueger KA, Grady
D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH,
Morrow M, et al: The effect of raloxifene on risk of breast cancer
in postmenopausal women: Results from the MORE randomized trial
Multiple outcomes of raloxifene evaluation. JAMA. 281:2189–2197.
1999.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ladea M and Prelipceanu D: Markers of
vulnerability in schizophrenia. J Med Life. 2:155–164.
2009.PubMed/NCBI
|
|
38
|
Ladea M, Barbu CM and Juckel G: Treatment
effectiveness in patients with schizophrenia as measured by the
ASSESS battery - first longitudinal data. Psychiatr Danub.
27:364–370. 2015.PubMed/NCBI
|
|
39
|
Shivakumar V and Venkatasubramanian G:
Successful use of adjuvant raloxifene treatment in
clozapine-resistant schizophrenia. Indian J Psychiatry.
54(394)2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kulkarni J, Gavrilidis E, Gwini SM,
Worsley R, Grigg J, Warren A, Gurvich C, Gilbert H, Berk M and
Davis SR: Effect of adjunctive raloxifene therapy on severity of
refractory schizophrenia in women: A randomized clinical trial.
JAMA Psychiatry. 73:947–954. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
de Boer J, Prikken M, Lei WU, Begemann M
and Sommer I: The effect of raloxifene augmentation in men and
women with a schizophrenia spectrum disorder: A systematic review
and meta-analysis. NPJ Schizophr. 4(1)2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Weiser M, Levi L, Burshtein S, Hagin M,
Matei VP, Podea D, Micluția I, Tiugan A, Păcală B, Grecu IG, et al:
Raloxifene plus antipsychotics versus placebo plus antipsychotics
in severely Ill decompensated postmenopausal women with
schizophrenia or schizoaffective disorder: A randomized controlled
trial. J Clin Psychiatry. 78:e758–e765. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Trifu S and Trifu AD: Receptor profiles of
atypical antipsychotic molecules. UPB Sci Bull. 82:113–128.
2020.
|
|
44
|
Ellis AJ, Hendrick VM, Williams R and Komm
BS: Selective estrogen receptor modulators in clinical practice: A
safety overview. Expert Opin Drug Saf. 14:921–934. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Vogel VG, Costantino JP, Wickerham DL,
Cronin WM and Wolmark N: The study of tamoxifen and raloxifene:
Preliminary enrollment data from a randomized breast cancer risk
reduction trial. Clin Breast Cancer. 3:153–159. 2002.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Cauley JA, Norton L, Lippman ME, Eckert S,
Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW,
et al: Continued breast cancer risk reduction in postmenopausal
women treated with raloxifene: 4-year results from the MORE trial
Multiple outcomes of raloxifene evaluation. Breast Cancer Res
Treat. 65:125–134. 2001.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Raveendranathan D, Shivakumar V, Jayaram
N, Rao NP and Venkatasubramanian G: Beneficial effects of add-on
raloxifene in schizophrenia. Arch Women Ment Health. 15:147–148.
2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Khan MM: Translational significance of
selective estrogen receptor modulators in psychiatric disorders.
Int J Endocrinol. 2018(9516592)2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Kulkarni J, de Castella A, Headey B,
Marston N, Sinclair K, Lee S, Gurvich C, Fitzgerald PB and Burger
H: Estrogens and men with schizophrenia: Is there a case for
adjunctive therapy? Schizophr Res. 125:278–283. 2011.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Weickert TW, Weinberg D, Lenroot R, Catts
SV, Wells R, Vercammen A, O'Donnell M, Galletly C, Liu D, Balzan R,
et al: Adjunctive raloxifene treatment improves attention and
memory in men and women with schizophrenia. Mol Psychiatry.
20:685–694. 2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Kindler J, Weickert CS, Skilleter AJ,
Catts SV, Lenroot R and Weickert TW: Selective estrogen receptor
modulation increases hippocampal activity during probabilistic
association learning in schizophrenia. Neuropsychopharmacology.
40:2388–2397. 2015.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Faraone SV, Chen WJ, Goldstein JM and
Tsuang MT: Sex differences in age at onset of schizophrenia. Br J
Psychiatry. 164:625–629. 1994.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Cotton SM, Lambert M, Schimmelmann BG,
Foley DL, Morley KI, McGorry PD and Conus P: Sex differences in
premorbid, entry, treatment, and outcome characteristics in a
treated epidemiological sample of 661 patients with first episode
psychosis. Schizophr Res. 114:17–24. 2009.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Döpfner M, Plück J, Berner W, Fegert JM,
Huss M, Lenz K, Schmeck K, Lehmkuhl U, Poustka F and Lehmkuhl G:
Mental disturbances in children and adolescents in Germany. Results
of a representative study: Age, sex and rater effects. Z Kinder
Jugendpsychiatr Psychother. 25:218–233. 1997.PubMed/NCBI(In German).
|
|
55
|
Kulkarni J, Gavrilidis E, Worsley R, Van
Rheenen T and Hayes E: The role of estrogen in the treatment of men
with schizophrenia. Int J Endocrinol Metab. 11:129–136.
2013.PubMed/NCBI View Article : Google Scholar
|
